English
简体中文
Total: £ 56.28
Published Date: 2025-04-23 | Pages: 77 | Tables: 80 | Medical Care
The global market for Leukocyte Adhesion Deficiency Management was valued at US$ 9412 million in the year 2024 and is projected to reach a revised size of US$ 18390 million by 2031, growing at a CAGR of 10.2% during the forecast period.
Leukocyte Adhesion Deficiency (LAD) is a rare primary immunodeficiency disorder characterized by defects in leukocyte adhesion molecules, impairing the ability of white blood cells to migrate to sites of infection. Management of LAD involves a multifaceted approach, including early diagnosis, aggressive treatment of infections, and prophylactic antibiotic therapy to prevent recurrent bacterial infections. In severe cases, hematopoietic stem cell transplantation (HSCT) remains the only curative option and is often recommended for long-term survival. Emerging therapies such as gene therapy are also under investigation, particularly for specific subtypes of LAD. The overall goal of management is to improve immune function, reduce infection frequency, and enhance the patient's quality of life through timely and individualized treatment strategies.
North American market for Leukocyte Adhesion Deficiency Management is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Leukocyte Adhesion Deficiency Management is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Leukocyte Adhesion Deficiency Management in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Leukocyte Adhesion Deficiency Management include Rocket Pharmaceuticals, Orchard Therapeutics, Avrobio, Inc., Magenta Therapeutics, Lonza Group, Bluebird Bio, Be The Match BioTherapies, CSL Behring, Gilead Sciences, Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Leukocyte Adhesion Deficiency Management, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Leukocyte Adhesion Deficiency Management.
The Leukocyte Adhesion Deficiency Management market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Leukocyte Adhesion Deficiency Management market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Leukocyte Adhesion Deficiency Management companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Rocket Pharmaceuticals
Orchard Therapeutics
Avrobio, Inc.
Magenta Therapeutics
Lonza Group
Bluebird Bio
Be The Match BioTherapies
CSL Behring
Gilead Sciences
Novartis
Segment by Type
Stem Cell Therapies
Surgery Transplantation
Other
Segment by Application
Hospital
Research Institution
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Leukocyte Adhesion Deficiency Management company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Leukocyte Adhesion Deficiency Management Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Stem Cell Therapies
1.2.3 Surgery Transplantation
1.2.4 Other
1.3 Market by Application
1.3.1 Global Leukocyte Adhesion Deficiency Management Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Research Institution
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Leukocyte Adhesion Deficiency Management Market Perspective (2020-2031)
2.2 Global Leukocyte Adhesion Deficiency Management Growth Trends by Region
2.2.1 Global Leukocyte Adhesion Deficiency Management Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Leukocyte Adhesion Deficiency Management Historic Market Size by Region (2020-2025)
2.2.3 Leukocyte Adhesion Deficiency Management Forecasted Market Size by Region (2026-2031)
2.3 Leukocyte Adhesion Deficiency Management Market Dynamics
2.3.1 Leukocyte Adhesion Deficiency Management Industry Trends
2.3.2 Leukocyte Adhesion Deficiency Management Market Drivers
2.3.3 Leukocyte Adhesion Deficiency Management Market Challenges
2.3.4 Leukocyte Adhesion Deficiency Management Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Leukocyte Adhesion Deficiency Management Players by Revenue
3.1.1 Global Top Leukocyte Adhesion Deficiency Management Players by Revenue (2020-2025)
3.1.2 Global Leukocyte Adhesion Deficiency Management Revenue Market Share by Players (2020-2025)
3.2 Global Top Leukocyte Adhesion Deficiency Management Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Leukocyte Adhesion Deficiency Management Revenue
3.4 Global Leukocyte Adhesion Deficiency Management Market Concentration Ratio
3.4.1 Global Leukocyte Adhesion Deficiency Management Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Leukocyte Adhesion Deficiency Management Revenue in 2024
3.5 Global Key Players of Leukocyte Adhesion Deficiency Management Head office and Area Served
3.6 Global Key Players of Leukocyte Adhesion Deficiency Management, Product and Application
3.7 Global Key Players of Leukocyte Adhesion Deficiency Management, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Leukocyte Adhesion Deficiency Management Breakdown Data by Type
4.1 Global Leukocyte Adhesion Deficiency Management Historic Market Size by Type (2020-2025)
4.2 Global Leukocyte Adhesion Deficiency Management Forecasted Market Size by Type (2026-2031)
5 Leukocyte Adhesion Deficiency Management Breakdown Data by Application
5.1 Global Leukocyte Adhesion Deficiency Management Historic Market Size by Application (2020-2025)
5.2 Global Leukocyte Adhesion Deficiency Management Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Leukocyte Adhesion Deficiency Management Market Size (2020-2031)
6.2 North America Leukocyte Adhesion Deficiency Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Leukocyte Adhesion Deficiency Management Market Size by Country (2020-2025)
6.4 North America Leukocyte Adhesion Deficiency Management Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Leukocyte Adhesion Deficiency Management Market Size (2020-2031)
7.2 Europe Leukocyte Adhesion Deficiency Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Leukocyte Adhesion Deficiency Management Market Size by Country (2020-2025)
7.4 Europe Leukocyte Adhesion Deficiency Management Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Leukocyte Adhesion Deficiency Management Market Size (2020-2031)
8.2 Asia-Pacific Leukocyte Adhesion Deficiency Management Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Leukocyte Adhesion Deficiency Management Market Size by Region (2020-2025)
8.4 Asia-Pacific Leukocyte Adhesion Deficiency Management Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Leukocyte Adhesion Deficiency Management Market Size (2020-2031)
9.2 Latin America Leukocyte Adhesion Deficiency Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Leukocyte Adhesion Deficiency Management Market Size by Country (2020-2025)
9.4 Latin America Leukocyte Adhesion Deficiency Management Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Leukocyte Adhesion Deficiency Management Market Size (2020-2031)
10.2 Middle East & Africa Leukocyte Adhesion Deficiency Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Leukocyte Adhesion Deficiency Management Market Size by Country (2020-2025)
10.4 Middle East & Africa Leukocyte Adhesion Deficiency Management Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Rocket Pharmaceuticals
11.1.1 Rocket Pharmaceuticals Company Details
11.1.2 Rocket Pharmaceuticals Business Overview
11.1.3 Rocket Pharmaceuticals Leukocyte Adhesion Deficiency Management Introduction
11.1.4 Rocket Pharmaceuticals Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025)
11.1.5 Rocket Pharmaceuticals Recent Development
11.2 Orchard Therapeutics
11.2.1 Orchard Therapeutics Company Details
11.2.2 Orchard Therapeutics Business Overview
11.2.3 Orchard Therapeutics Leukocyte Adhesion Deficiency Management Introduction
11.2.4 Orchard Therapeutics Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025)
11.2.5 Orchard Therapeutics Recent Development
11.3 Avrobio, Inc.
11.3.1 Avrobio, Inc. Company Details
11.3.2 Avrobio, Inc. Business Overview
11.3.3 Avrobio, Inc. Leukocyte Adhesion Deficiency Management Introduction
11.3.4 Avrobio, Inc. Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025)
11.3.5 Avrobio, Inc. Recent Development
11.4 Magenta Therapeutics
11.4.1 Magenta Therapeutics Company Details
11.4.2 Magenta Therapeutics Business Overview
11.4.3 Magenta Therapeutics Leukocyte Adhesion Deficiency Management Introduction
11.4.4 Magenta Therapeutics Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025)
11.4.5 Magenta Therapeutics Recent Development
11.5 Lonza Group
11.5.1 Lonza Group Company Details
11.5.2 Lonza Group Business Overview
11.5.3 Lonza Group Leukocyte Adhesion Deficiency Management Introduction
11.5.4 Lonza Group Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025)
11.5.5 Lonza Group Recent Development
11.6 Bluebird Bio
11.6.1 Bluebird Bio Company Details
11.6.2 Bluebird Bio Business Overview
11.6.3 Bluebird Bio Leukocyte Adhesion Deficiency Management Introduction
11.6.4 Bluebird Bio Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025)
11.6.5 Bluebird Bio Recent Development
11.7 Be The Match BioTherapies
11.7.1 Be The Match BioTherapies Company Details
11.7.2 Be The Match BioTherapies Business Overview
11.7.3 Be The Match BioTherapies Leukocyte Adhesion Deficiency Management Introduction
11.7.4 Be The Match BioTherapies Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025)
11.7.5 Be The Match BioTherapies Recent Development
11.8 CSL Behring
11.8.1 CSL Behring Company Details
11.8.2 CSL Behring Business Overview
11.8.3 CSL Behring Leukocyte Adhesion Deficiency Management Introduction
11.8.4 CSL Behring Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025)
11.8.5 CSL Behring Recent Development
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Details
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Leukocyte Adhesion Deficiency Management Introduction
11.9.4 Gilead Sciences Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025)
11.9.5 Gilead Sciences Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Leukocyte Adhesion Deficiency Management Introduction
11.10.4 Novartis Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025)
11.10.5 Novartis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Leukocyte Adhesion Deficiency Management Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Stem Cell Therapies
Table 3. Key Players of Surgery Transplantation
Table 4. Key Players of Other
Table 5. Global Leukocyte Adhesion Deficiency Management Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Leukocyte Adhesion Deficiency Management Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Leukocyte Adhesion Deficiency Management Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Leukocyte Adhesion Deficiency Management Market Share by Region (2020-2025)
Table 9. Global Leukocyte Adhesion Deficiency Management Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Leukocyte Adhesion Deficiency Management Market Share by Region (2026-2031)
Table 11. Leukocyte Adhesion Deficiency Management Market Trends
Table 12. Leukocyte Adhesion Deficiency Management Market Drivers
Table 13. Leukocyte Adhesion Deficiency Management Market Challenges
Table 14. Leukocyte Adhesion Deficiency Management Market Restraints
Table 15. Global Leukocyte Adhesion Deficiency Management Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Leukocyte Adhesion Deficiency Management Market Share by Players (2020-2025)
Table 17. Global Top Leukocyte Adhesion Deficiency Management Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Leukocyte Adhesion Deficiency Management as of 2024)
Table 18. Ranking of Global Top Leukocyte Adhesion Deficiency Management Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Leukocyte Adhesion Deficiency Management Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Leukocyte Adhesion Deficiency Management, Headquarters and Area Served
Table 21. Global Key Players of Leukocyte Adhesion Deficiency Management, Product and Application
Table 22. Global Key Players of Leukocyte Adhesion Deficiency Management, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Leukocyte Adhesion Deficiency Management Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Leukocyte Adhesion Deficiency Management Revenue Market Share by Type (2020-2025)
Table 26. Global Leukocyte Adhesion Deficiency Management Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Leukocyte Adhesion Deficiency Management Revenue Market Share by Type (2026-2031)
Table 28. Global Leukocyte Adhesion Deficiency Management Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Leukocyte Adhesion Deficiency Management Revenue Market Share by Application (2020-2025)
Table 30. Global Leukocyte Adhesion Deficiency Management Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Leukocyte Adhesion Deficiency Management Revenue Market Share by Application (2026-2031)
Table 32. North America Leukocyte Adhesion Deficiency Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Leukocyte Adhesion Deficiency Management Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Leukocyte Adhesion Deficiency Management Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Leukocyte Adhesion Deficiency Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Leukocyte Adhesion Deficiency Management Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Leukocyte Adhesion Deficiency Management Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Leukocyte Adhesion Deficiency Management Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Leukocyte Adhesion Deficiency Management Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Leukocyte Adhesion Deficiency Management Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Leukocyte Adhesion Deficiency Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Leukocyte Adhesion Deficiency Management Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Leukocyte Adhesion Deficiency Management Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Leukocyte Adhesion Deficiency Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Leukocyte Adhesion Deficiency Management Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Leukocyte Adhesion Deficiency Management Market Size by Country (2026-2031) & (US$ Million)
Table 47. Rocket Pharmaceuticals Company Details
Table 48. Rocket Pharmaceuticals Business Overview
Table 49. Rocket Pharmaceuticals Leukocyte Adhesion Deficiency Management Product
Table 50. Rocket Pharmaceuticals Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025) & (US$ Million)
Table 51. Rocket Pharmaceuticals Recent Development
Table 52. Orchard Therapeutics Company Details
Table 53. Orchard Therapeutics Business Overview
Table 54. Orchard Therapeutics Leukocyte Adhesion Deficiency Management Product
Table 55. Orchard Therapeutics Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025) & (US$ Million)
Table 56. Orchard Therapeutics Recent Development
Table 57. Avrobio, Inc. Company Details
Table 58. Avrobio, Inc. Business Overview
Table 59. Avrobio, Inc. Leukocyte Adhesion Deficiency Management Product
Table 60. Avrobio, Inc. Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025) & (US$ Million)
Table 61. Avrobio, Inc. Recent Development
Table 62. Magenta Therapeutics Company Details
Table 63. Magenta Therapeutics Business Overview
Table 64. Magenta Therapeutics Leukocyte Adhesion Deficiency Management Product
Table 65. Magenta Therapeutics Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025) & (US$ Million)
Table 66. Magenta Therapeutics Recent Development
Table 67. Lonza Group Company Details
Table 68. Lonza Group Business Overview
Table 69. Lonza Group Leukocyte Adhesion Deficiency Management Product
Table 70. Lonza Group Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025) & (US$ Million)
Table 71. Lonza Group Recent Development
Table 72. Bluebird Bio Company Details
Table 73. Bluebird Bio Business Overview
Table 74. Bluebird Bio Leukocyte Adhesion Deficiency Management Product
Table 75. Bluebird Bio Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025) & (US$ Million)
Table 76. Bluebird Bio Recent Development
Table 77. Be The Match BioTherapies Company Details
Table 78. Be The Match BioTherapies Business Overview
Table 79. Be The Match BioTherapies Leukocyte Adhesion Deficiency Management Product
Table 80. Be The Match BioTherapies Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025) & (US$ Million)
Table 81. Be The Match BioTherapies Recent Development
Table 82. CSL Behring Company Details
Table 83. CSL Behring Business Overview
Table 84. CSL Behring Leukocyte Adhesion Deficiency Management Product
Table 85. CSL Behring Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025) & (US$ Million)
Table 86. CSL Behring Recent Development
Table 87. Gilead Sciences Company Details
Table 88. Gilead Sciences Business Overview
Table 89. Gilead Sciences Leukocyte Adhesion Deficiency Management Product
Table 90. Gilead Sciences Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025) & (US$ Million)
Table 91. Gilead Sciences Recent Development
Table 92. Novartis Company Details
Table 93. Novartis Business Overview
Table 94. Novartis Leukocyte Adhesion Deficiency Management Product
Table 95. Novartis Revenue in Leukocyte Adhesion Deficiency Management Business (2020-2025) & (US$ Million)
Table 96. Novartis Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
Table 100. Authors List of This Report
List of Figures
Figure 1. Leukocyte Adhesion Deficiency Management Picture
Figure 2. Global Leukocyte Adhesion Deficiency Management Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Leukocyte Adhesion Deficiency Management Market Share by Type: 2024 VS 2031
Figure 4. Stem Cell Therapies Features
Figure 5. Surgery Transplantation Features
Figure 6. Other Features
Figure 7. Global Leukocyte Adhesion Deficiency Management Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Leukocyte Adhesion Deficiency Management Market Share by Application: 2024 VS 2031
Figure 9. Hospital Case Studies
Figure 10. Research Institution Case Studies
Figure 11. Other Case Studies
Figure 12. Leukocyte Adhesion Deficiency Management Report Years Considered
Figure 13. Global Leukocyte Adhesion Deficiency Management Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Leukocyte Adhesion Deficiency Management Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Leukocyte Adhesion Deficiency Management Market Share by Region: 2024 VS 2031
Figure 16. Global Leukocyte Adhesion Deficiency Management Market Share by Players in 2024
Figure 17. Global Leukocyte Adhesion Deficiency Management Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by Leukocyte Adhesion Deficiency Management Revenue in 2024
Figure 19. North America Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Leukocyte Adhesion Deficiency Management Market Share by Country (2020-2031)
Figure 21. United States Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Leukocyte Adhesion Deficiency Management Market Share by Country (2020-2031)
Figure 25. Germany Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Leukocyte Adhesion Deficiency Management Market Share by Region (2020-2031)
Figure 33. China Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Leukocyte Adhesion Deficiency Management Market Share by Country (2020-2031)
Figure 41. Mexico Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Leukocyte Adhesion Deficiency Management Market Share by Country (2020-2031)
Figure 45. Turkey Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Leukocyte Adhesion Deficiency Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Rocket Pharmaceuticals Revenue Growth Rate in Leukocyte Adhesion Deficiency Management Business (2020-2025)
Figure 49. Orchard Therapeutics Revenue Growth Rate in Leukocyte Adhesion Deficiency Management Business (2020-2025)
Figure 50. Avrobio, Inc. Revenue Growth Rate in Leukocyte Adhesion Deficiency Management Business (2020-2025)
Figure 51. Magenta Therapeutics Revenue Growth Rate in Leukocyte Adhesion Deficiency Management Business (2020-2025)
Figure 52. Lonza Group Revenue Growth Rate in Leukocyte Adhesion Deficiency Management Business (2020-2025)
Figure 53. Bluebird Bio Revenue Growth Rate in Leukocyte Adhesion Deficiency Management Business (2020-2025)
Figure 54. Be The Match BioTherapies Revenue Growth Rate in Leukocyte Adhesion Deficiency Management Business (2020-2025)
Figure 55. CSL Behring Revenue Growth Rate in Leukocyte Adhesion Deficiency Management Business (2020-2025)
Figure 56. Gilead Sciences Revenue Growth Rate in Leukocyte Adhesion Deficiency Management Business (2020-2025)
Figure 57. Novartis Revenue Growth Rate in Leukocyte Adhesion Deficiency Management Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
